| HOME >> MEDICINE >> TECHNOLOGY |
(65)(16)114(112)Change in cash and cash equivalents
14,303(6,799)(15,493)(31,205)Cash and cash equivalents, beginning of period
28,48665,08158,28289,487Cash and cash equivalents, end of period
$ 42,789$ 58,282$
42,789$ 58,282
LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,20122012(unaudited)(unaudited)Income from operations
$
7,255$
22,716Strategic study consulting costs
-1,096GDx acquisition related costs
1,2974,263Adjusted income from operations
$
8,552$
28,075Net income
$
4,252$
2,407Strategic study consulting costs
-1,096GDx acquisition related costs
1,2974,263Income tax effect of the above items
(404)(1,588)Adjusted net income
$
5,145$
,178Adjusted net income per share, basic
$
.13$
.40Shares used in computing adjusted net income per share, basic
40,72440,927Adjusted net income per share, diluted
$
.12$
.39Shares used in computing adjusted net income per share, diluted
41,33241,884The Company makes reference in this release to "non-GAAP operating income" and "non-GAAP net income" which exclude the impact of acquisition and strategic study consulting expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepa
'/>"/>
| SOURCE Luminex Corporation Copyright©2012 PR Newswire. All rights reserved |